PRAX: praxismedicines.com PEG Multiple
Anticipation of late-stage trial results for epilepsy drugs creates a positive backdrop for Praxis Precision Medicines (PRAX), while R&D costs are already priced in. A diversified portfolio of psychiatric disorder treatments mitigates business risks. The PEG fair value trend confirms this balance, where the 0.00 value captures the final metric. An innovative molecule discovery platform for ion channels ensures leadership in CNS therapy.
Praxis Precision Medicines (PRAX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Praxis Precision Medicines|PRAX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital praxismedicines.com|PRAX - Company Debts|Debts to Book Capitalization Ratio Praxis Medicines|PRAX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Praxis Precision Medicines|Immediate Liquidity praxismedicines.com
- net income and valuation multiples indicators:
PRAX - Net Profit|Future Profit Praxis Precision Medicines|PRAX - P/E Multiple|Market Cap to Projected Earnings Praxis Corp|PRAX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Praxis Medicines|PRAX - Operating profit EBITDA|Net earnings per share for the last four quarters Praxis Precision Medicines|PRAX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months praxismedicines.com|PRAX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Praxis Precision Medicines
Fundamental company analysis:Praxis Precision Medicines Inc - PRAX
The PEG ratio compares a business's market value to its earnings growth, determining whether capitalization is justified by current revenue expansion. For Praxis Precision Medicines (PRAX), which develops brain ion channel therapies, the PEG ratio trend reflects the fairness of the valuation regarding future insurance payouts, confirming the asset's fundamental stability when values remain below one.
Competitors of Praxis Precision Medicines
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|PEG Multiple NBIX (Neurocrine Biosciences Inc)|PEG Multiple Regencell Corp RGC|AXSM: Price/Earnings to Growth Multiple|ACAD (acadia-pharm.com) - Growth-Adjusted P/E Ratio|XENE: PEG Multiple|VKTX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Supernus Pharma|Catalyst Corp (CPRX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Biohaven BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Market Cap to Earnings and Growth Ratio|TRVI - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio AVXL (Anavex Life Sciences Corp)|CBLL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Prothena (PRTA)|ALEC (Alector Inc.) - PEG Multiple|Price/Earnings to Growth Multiple Annexon Biosciences (ANNX)|PEG Multiple OMER|Growth-Adjusted Market Cap to Net Income Neurogene Therapeutics|Price/Earnings to Growth Ratio AC Immune ACIU|Growth-Adjusted Market Cap to Net Income voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Scilex Holding SCLX|Tevogen Bio Holdings, Inc. (TVGN) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Alpha Cognition Inc. (ACOG)|Price/Earnings to Growth Ratio Cognition Therapeutics|Growth-Adjusted P/E Ratio IKT (inhibikase.com)|Price/Earnings to Growth Multiple SAVA (Cassava Sciences)|ASRT (assertiotx.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Coya Therapeutics COYA|VTGN - Price/Earnings to Growth Multiple|Ovid Rx - PEG Multiple|Price to Earnings Adjusted for Growth Rate acumenpharm.com|CRVO: PEG Multiple|Growth-Adjusted P/E Ratio ATHE|CLNN (Clene Inc) - PEG Multiple|PepGen Corp (PEPG) - Growth-Adjusted Market Cap to Net Income|PEG Multiple JUNS|Price/Earnings to Growth Multiple relmada.com RLMD|PEG Multiple ANVS (Annovis Bio)|Growth-Adjusted Market Cap to Net Income Grace Therapeutics Inc (GRCE)|AIFF - Price/Earnings to Growth Ratio|KLTO (Klotho Neurosciences Inc) - Growth-Adjusted P/E Ratio|NRSN: PEG Multiple|Price to Earnings Adjusted for Growth Rate revivapharma.com (RVPH)|Price/Earnings to Growth Ratio MetaVia Inc.|NeurAxis Inc. (NRXS) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Helius Medical (HSDT)|PASG: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|Growth-Adjusted Payback Ratio NERV|Athira Pharma - PEG Multiple|ADXN - PEG Multiple|ALZN (alzamend.com) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio CYCN|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Growth-Adjusted P/E Ratio KTTA (Pasithea)|PEG Multiple CRGT|ATXI - Price to Earnings Adjusted for Growth Rate|Brainstorm Cell Therapeutics, Inc. - Price/Earnings to Growth Multiple|PEG Multiple Cara Therapeutics Inc CARA|CHRO - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Longboard Pharmaceuticals Inc (LBPH)|Price/Earnings to Growth Ratio Marinus|NKGen Biotech Corp - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|PEG Multiple SNPX (Synaptogenix)|PEG Multiple Trevena Inc. TRVN|VIGL: Price/Earnings to Growth Multiple|WENA (Anew Medical Inc.) - Growth-Adjusted P/E Ratio|CERE: PEG Multiple
